These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120 [TBL] [Abstract][Full Text] [Related]
46. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Scheen AJ Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969 [TBL] [Abstract][Full Text] [Related]
47. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB; BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881 [TBL] [Abstract][Full Text] [Related]
48. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. Fadah K; Alashi A; Deoker A Curr Cardiol Rep; 2022 Jan; 24(1):17-22. PubMed ID: 35000149 [TBL] [Abstract][Full Text] [Related]
49. DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease. Sonoda K; Saguil A Am Fam Physician; 2022 Jul; 106(1):24-25. PubMed ID: 35839371 [No Abstract] [Full Text] [Related]
50. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor? Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123 [TBL] [Abstract][Full Text] [Related]
51. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC Ann Intern Med; 2021 Nov; 174(11):1528-1541. PubMed ID: 34570599 [TBL] [Abstract][Full Text] [Related]
52. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Karagiannis T; Tsapas A; Athanasiadou E; Avgerinos I; Liakos A; Matthews DR; Bekiari E Diabetes Res Clin Pract; 2021 Apr; 174():108737. PubMed ID: 33705820 [TBL] [Abstract][Full Text] [Related]
53. Time to Follow the Evidence: Glycemic Control and Cardiovascular Benefits of New Diabetes Medications. Draznin B; Hirsch IB Am J Med; 2021 Apr; 134(4):420-422. PubMed ID: 33434557 [No Abstract] [Full Text] [Related]
54. GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns. Dimitriadis GD; Lambadiari V J Clin Endocrinol Metab; 2023 Mar; 108(4):e52-e53. PubMed ID: 36507904 [No Abstract] [Full Text] [Related]
55. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints. Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914 [TBL] [Abstract][Full Text] [Related]
56. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928 [TBL] [Abstract][Full Text] [Related]
58. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors]. Verburg AFE; van den Donk M; Wiersma T Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706 [TBL] [Abstract][Full Text] [Related]
59. New Therapeutic Strategies for Type 2 Diabetes Yehya A; Sadhu AR Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014 [TBL] [Abstract][Full Text] [Related]
60. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Muzurović E; Mikhailidis DP Expert Opin Pharmacother; 2020 Dec; 21(17):2125-2135. PubMed ID: 32697112 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]